Nicholas Investment Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

Nicholas Investment Partners’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-69,103	Closed	-$2.27M	–	358
2016 Q3	$2.27M	Buy	+69,103	New	+$2.1M	0.15%	250
2016 Q1	–	Sell	-59,198	Closed	-$1.96M	–	351
2015 Q4	$1.96M	Buy	59,198 +30,944	+110%	+$1.05M	0.14%	258
2015 Q3	$926K	Sell	28,254 -14,001	-33%	-$595K	0.07%	284
2015 Q2	$2.24M	Sell	42,255 -13,508	-24%	-$491K	0.14%	251
2015 Q1	$1.61M	Buy	55,763 +6,325	+13%	+$174K	0.1%	277
2014 Q4	$1.44M	Buy	49,438 +97	+0.2%	+$1.74K	0.09%	276
2014 Q3	$626K	Sell	49,341 -1,115	-2%	-$16.9K	0.04%	290
2014 Q2	$1.01M	Buy	+50,456	New	+$710K	0.06%	265

Other funds holding ALDR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Nicholas Investment Partners's ALDR Position: Q4 2016 in Review

Nicholas Investment Partners sold out of Alder Biopharmaceuticals (ALDR) in Q4 2016, closing a stake of 69,103 shares — an estimated $2.27M sold.

Nicholas Investment Partners first reported a position in ALDR in Q2 2014 and held it in 8 quarters. The position peaked at $2.27M in Q3 2016. 145 funds tracked by Wall St. Rank hold ALDR as of Q4 2016.

Nicholas Investment Partners reported no remaining Alder Biopharmaceuticals position as of Q4 2016 after selling out during the quarter.
Nicholas Investment Partners sold 69,103 Alder Biopharmaceuticals shares in Q4 2016, an estimated $2.27M.
Nicholas Investment Partners first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 8 quarters.
Nicholas Investment Partners's Alder Biopharmaceuticals position peaked at $2.27M in Q3 2016.
145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2016.

Based on Nicholas Investment Partners's 13F filing for Q4 2016, filed 10 Feb 2017.